# Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

> **NCT02520063** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Everolimus
- **DRUG:** TRC105

## Key facts

- **NCT ID:** NCT02520063
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520063, "Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02520063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*